The Minimal Residual Disease Testing Market Segment analysis for 2026 reveals a distinct shift in how diagnostics are consumed. While the hematological malignancies segment still commands over 60% of the market share, the solid tumor segment is growing at the fastest compound annual rate. This is largely due to the "neoadjuvant" application, where MRD testing is used before and after...